Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China flag China · Delayed Price · Currency is CNY
33.93
-0.26 (-0.76%)
Mar 9, 2026, 3:00 PM CST
82.91%
Market Cap 13.55B
Revenue (ttm) 662.52M
Net Income (ttm) -970.18M
Shares Out 399.40M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,165,046
Average Volume 5,673,379
Open 33.60
Previous Close 34.19
Day's Range 32.91 - 34.20
52-Week Range 16.71 - 63.59
Beta 0.91
RSI 42.08
Earnings Date Mar 25, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; and JUNMAIKANG, an autoimmune Adalimumab injection. Its oncology product pipeline includes 9MW2821, a Nectin-4 t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 1,362
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688062
Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -970.18 million, -7.06% less than in 2024.

Financial Statements

News

There is no news available yet.